National Medical Products Administration

And then in 2025, five of the 10 largest pharma R&D licensing transactions globally involved Chinese companies.

China's NMPA approved 43 innovative drugs in the first half of 2025 alone, up 59% from the same period the previous year.

And this is not a trend, right? It's a structural shift in where pharma innovation is coming from.

And for decades, the model was straightforward.

The competition has been and is continuing to heat up, which is also why a regulator on the other side of the world decided this month that the data coming off of these devices needs to follow stricter rules.

According to this article by The Tech Times, on September 15th, China's National Medical Products Administration, their version of the FDA, issued the world's first binding technical standard for how AI in a medical brain computer interface handles brainwave data.

It covers five stages, collection, processing, labeling, storage, and access.

It takes effect September 1st, 2027.

Secondly, regulatory reform and capacity building.

So China's version of the U.S. Food and Drug Administration, called the NMPA, was recreated and its chain of command was prioritized so that it reported more directly to the state council and didn't need as many levels of approval through the governance chain, allowing it greater control and accountability.

And also there was massive clampdown on corruption.

You know, the food and drug world has always been one of the richest in terms of opportunity for things handed under the table.

I think what people are talking about on the ground here when you ask, you know, what has led to this sudden boom, you have this years of stewardship by the government.

You have these reforms to speed up how the NMPA, the Chinese FDA regulates drugs.

You have this rich group of young scientists and burgeoning number of STEM grads.

You have the scientists who went overseas and came back.

He has nearly three decades taking medical and life science products from sketch on a whiteboard to FDA cleared manufacturing, ready reality.

Their work includes microports to my system, the first time to develop forearm laparoscopic robot to earn NMPA marketing approval and design and engineering work on intuitive surgical da Vinci and ion platforms, which passed 3.1 million procedures in 2025.

Michael didn't start in med tech.

He spent his first 15 years directing engineering at Xerox, co-founding Destiny Networks, where he scaled a team to 60 engineers building smart remote controls and leading engineers at home, engineering at home director, where he turned an underperforming product line into a 22% sales increase.

There's a whole other world out there.

And even if you go with MDSAP, you got Brazil, Australia, Canada, Japan, and then you've got UMDR.

We mentioned NMPA China earlier.

And so how do you look at that? Is that another persona in your mind or is that just inputs that could influence the design or does it yes or no?

China has unveiled the world's first product standard for AI-powered brain-computer interface medical devices that process brainwave data, known as EEG.

The National Medical Products Administration said it will address problems, including the dataset's inconsistent quality control.

China defeated the Philippines, the defending champion, 105-61 in the Asian Games men's basketball tournament.

Wang Junjie led all scorers with 20 points and added 14 rebounds.

China has unveiled the world's first product standard for AI-powered brain-computer interface medical devices that process brainwave data, known as EEG.

The National Medical Products Administration said it will address problems, including the dataset's inconsistent quality control.

The new standard will take effect on September 1 next year.

And that's the news.